Furthermore, in 2019, the Food and Drug Administration (FDA) approved pembrolizumab as a single agent for patients with head and neck SCC, whose tumors express a PD-L1 combined positive score ≥1, thus officializing the first immunotherapeutic modality regarding this group of cancers [2]. Here, CD274 is linked to cancer.